Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Saudi International Ex...Saudi International Expo
Not Confirmed
Not Confirmed
28-30 October, 2024
SupplySide West 2024SupplySide West 2024
Not Confirmed
Not Confirmed
28 October-01 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Saudi International Ex...Saudi International Expo
Industry Trade Show
Not Confirmed
28-30 October, 2024
SupplySide West 2024SupplySide West 2024
Industry Trade Show
Not Confirmed
28 October-01 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/due-to-its-20-year-mastery-in-micronization-inke-has-emerged-a-cornerstone-in-treating-global-respiratory-diseases
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions
09 Jan 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/neuroderm-announces-highly-positive-results-from-the-pivotal-phase-iii-boundless-trial-evaluating-nd0612-in-parkinsons-disease-patients-with-motor-fluctuations-301715860.html
Details:
ND0612 is an investigative drug-device combination therapy – a 24 hours/day, continuous subcutaneous infusion of liquid levodopa/carbidopa (LD/CD) for people with Parkinson’s disease (PD) experiencing motor fluctuations.
Lead Product(s): Etilevodopa,Carbidopa
Therapeutic Area: Neurology Brand Name: ND0612
Study Phase: Phase IIIProduct Type: Small molecule
Recipient: Mitsubishi Tanabe Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Lead Product(s) : Etilevodopa,Carbidopa
Therapeutic Area : Neurology
Highest Development Status : Phase III
Recipient : Mitsubishi Tanabe Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ND0612 is an investigative drug-device combination therapy – a 24 hours/day, continuous subcutaneous infusion of liquid levodopa/carbidopa (LD/CD) for people with Parkinson’s disease (PD) experiencing motor fluctuations.
Brand Name : ND0612
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 28, 2023
Details:
ND0612 is a continuous, subcutaneous infusion levodopa/carbidopa delivery system under development for patients with Parkinson's disease (PD) and motor fluctuations.
Lead Product(s): Etilevodopa,Carbidopa
Therapeutic Area: Neurology Brand Name: ND0612
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Lead Product(s) : Etilevodopa,Carbidopa
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ND0612 is a continuous, subcutaneous infusion levodopa/carbidopa delivery system under development for patients with Parkinson's disease (PD) and motor fluctuations.
Brand Name : ND0612
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 09, 2023
Details:
Long-term safety data from the Phase 2b BeyoND study demonstrated a positive ND0612, an investigational drug-device combination safety and tolerability profile beyond one year in people with Parkinson's disease.
Lead Product(s): Etilevodopa,Carbidopa
Therapeutic Area: Neurology Brand Name: ND0612
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Lead Product(s) : Etilevodopa,Carbidopa
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Long-term safety data from the Phase 2b BeyoND study demonstrated a positive ND0612, an investigational drug-device combination safety and tolerability profile beyond one year in people with Parkinson's disease.
Brand Name : ND0612
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 04, 2022
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?